posted on 2019-03-04, 16:02authored byluc bertrand, Fannie Méroth, Ana leda, Michal Toborek
In
the era of highly active antiretroviral therapy, the HIV prognostic has changed
from a deadly to a chronic disease. While the virus is repressed, several
co-morbidities, including cardiovascular disease are still present in long term
survivors. HIV positive individuals are more at risk of having strokes and also
suffer from a less favorable recovery prognostic. Our hypothesis is that
despite efficient HAART, residual HIV presence can contribute to stroke
severity. In addition, we also hypothesize that viral reservoirs in the brain
contribute to injury and that efficient treatment using high CNS penetration
effectiveness (CPE) drugs could benefit disease outcome. Previous publications
in our laboratory, based on the EcoHIV mouse model, demonstrated that infection
affects the integrity of the functions of the blood-brain barrier. In the current
study, we observed that infection by EcoHIV resulted in a significant increase
in infract size both at early and late post-stroke when compared to mock
infected animals. In addition, a recovery from stroke injury was seen in
control animals, this reduction was not visible in EcoHIV infected mice. Upon
further examination, we were able to demonstrate that the induction of stroke
resulted in an increase in HIV presence in the affected hemisphere, with infected
cells situated primarily near or at the border of the infract area. The
majority of cells harboring the virus were from the macrophage/microglial
lineage. We next employed several immune markers to examine if the immune
reaction to the tissue injury and the more prominent viral presence could be
responsible for the delay in infract recovery. We observed a trend for an
increase in inflammatory markers in EcoHIV infected mice, especially those
associated with the monocyte/macrophage/neutrophil response. We are currently
investigating the potential therapeutic efficacy of targeting the HIV CNS
reservoir using a high CNS penetrating efficacy therapy. The successful
implementation of this regiment would be highly beneficial in HIV patients at risk
of cerebrovascular disease.